GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Vision SA (XPAR:GV) » Definitions » EV-to-EBITDA

Genomic Vision (XPAR:GV) EV-to-EBITDA : -0.22 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Genomic Vision EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genomic Vision's enterprise value is €1.66 Mil. Genomic Vision's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.52 Mil. Therefore, Genomic Vision's EV-to-EBITDA for today is -0.22.

The historical rank and industry rank for Genomic Vision's EV-to-EBITDA or its related term are showing as below:

XPAR:GV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.12   Med: -1.29   Max: 0.39
Current: -0.22

During the past 10 years, the highest EV-to-EBITDA of Genomic Vision was 0.39. The lowest was -38.12. And the median was -1.29.

XPAR:GV's EV-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 16.465 vs XPAR:GV: -0.22

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Genomic Vision's stock price is €0.0018. Genomic Vision's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.097. Therefore, Genomic Vision's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Genomic Vision EV-to-EBITDA Historical Data

The historical data trend for Genomic Vision's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Vision EV-to-EBITDA Chart

Genomic Vision Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 -3.48 -8.85 -2.41 -0.99

Genomic Vision Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.41 - -0.99 -

Competitive Comparison of Genomic Vision's EV-to-EBITDA

For the Diagnostics & Research subindustry, Genomic Vision's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Vision's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Vision's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genomic Vision's EV-to-EBITDA falls into.



Genomic Vision EV-to-EBITDA Calculation

Genomic Vision's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1.661/-7.523
=-0.22

Genomic Vision's current Enterprise Value is €1.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genomic Vision's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-7.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomic Vision  (XPAR:GV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genomic Vision's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0018/-0.097
=At Loss

Genomic Vision's share price for today is €0.0018.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genomic Vision's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.097.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Genomic Vision EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genomic Vision's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Vision (XPAR:GV) Business Description

Traded in Other Exchanges
N/A
Address
80-84 rue des Meuniers, Green Square, Batiment E, Bagneux, FRA, 92220
Genomic Vision SA is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics.